Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 7/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211038 | 1.00 | LMNA (0.56) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL31679985 | 0.88 | LMNA (0.69) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876014 | 0.84 | MEN1 (0.62) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876355 | 0.80 | MEN1 (0.63) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876095 | 0.80 | LMNA (0.69) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876644 | 0.78 | MEN1 (0.66) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876169 | 0.77 | MEN1 (0.72) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876007 | 0.77 | LMNA (0.80) | LMNAMEN1KMT2APKMTHRB | |
| SCHEMBL24876238 | 0.76 | PKM (0.34) | MEN1KMT2APKMALDH1A1 | |
| SCHEMBL24876241 | 0.76 | LMNA (0.78) | LMNAMEN1KMT2APKMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367103-B1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| WO-2023280970-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | SERPINB1, LTA, SERPINC1 | LMNA 1232/4885MEN1 3717/4885KMT2A 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.